BRIGHT MINDS BIOSCIENCES Logo
CA10919W1086

BRIGHT MINDS BIOSCIENCES

Ins Portfolio

Kurse werden geladen...

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +76,64(+155,55%). Der Median liegt bei +76,64(+155,55%).

Kaufen
  2
Halten
  0
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

  • Foto von SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

    SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

    TAMPA, FL, March 06, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC (“Scienture”), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. (“Kindeva”)), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.» Mehr auf globenewswire.com

  • Foto von Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101

    Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101

    Company's BMB-101 targets drug-resistant epilepsy, aiming for a multibillion-dollar market by treating patients unresponsive to standard anti-seizure medications. Company's phase 2 trial for Absence Epilepsy and DEE could have data released by 2026, potentially establishing it as a best-in-class 5-HT2C receptor agonist. The company has a $35 million private placement, extending its cash runway beyond 2026 and supporting its pipeline, including drugs for depression, PTSD, and anxiety.» Mehr auf seekingalpha.com

  • Foto von Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

    Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

    -- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an advisory capacity.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte BRIGHT MINDS BIOSCIENCES einen Umsatz von 0,00 und ein Nettoeinkommen von +33,22k
(EUR)Dez. 2024
YOY
Umsatz0,00-
Bruttoeinkommen0,00-
Nettoeinkommen+33,22k102,89%
EBITDA1,07 Mio5,46%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+229,09 Mio
Anzahl Aktien
7,04 Mio
52 Wochen-Hoch/Tief
+71,25 - +0,84
DividendenNein
Beta
0,67
KGV (PE Ratio)
301,17
KGWV (PEG Ratio)
4,62
KBV (PB Ratio)
+5,56
KUV (PS Ratio)
0,00

Unternehmensprofil

Bright Minds Biosciences Inc. ist ein präklinisches Biowissenschaftsunternehmen, das 5-HT-Medikamente (Serotonin) entwickelt, um das Leben von Patienten mit schweren und lebensverändernden Krankheiten zu verbessern. Sein Portfolio an selektiven 5-HT-Rezeptor-Agonisten umfasst 5-HT2C, 5-HT2A und 5-HT2C/A für die Behandlung von Epilepsie, Schmerzen und Neuropsychiatrie. Das Unternehmen arbeitet mit den National Institutes of Health für die Behandlung von Epilepsie, der University of Texas Medical Branch zur Behandlung von Impulskontrollstörungen wie Binge Eating und dem Medical College of Wisconsin zusammen. Das Unternehmen wurde 2019 gegründet und hat seinen Hauptsitz in Vancouver, Kanada.

Name
BRIGHT MINDS BIOSCIENCES
CEO
Ian McDonald
SitzVancouver, bc
Kanada
Website
Industrie
Chemikalien
Börsengang
Mitarbeiter0

Ticker Symbole

BörseSymbol
NASDAQ
DRUG
🍪

Parqet nutzt Cookies.Erfahre Mehr